NCT02171026已完成1 期
Relative Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of 150 mg Dabigatran Etexilate b.i.d. With or Without 600 mg Amiodarone as Single Dose in Healthy Male and Female Volunteers (an Open-Label, Multiple-Dose, Group-Comparison Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- AUCτ,ss (area under the concentration time curve of the analyte in plasma over one steady state dosing interval)
研究概览
简要总结
Investigation of the bioavailability, safety and tolerability of dabigatran with and without concomitant administration of amiodarone and the bioavailability of amiodarone and desethylamiodarone after administration of a single dose of amiodarone with and without dabigatran
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males and females according to the following criteria:
- •Based upon a complete medical history, including the physical examination, vital signs (BP, pulse rate (PR)), 12-lead ECG, clinical laboratory tests
- •Aged >=18 and <=55 years
- •Body mass index (BMI) >=18.5 and BMI <=29.9 kg/m2
- •Signed and dated written informed consent prior to admission to the study according to GCP and local legislation
排除标准
- •Clinically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Relevant surgery of gastrointestinal tract
- •History of any bleeding disorder or acute blood coagulation defect
- •Diseases of the central nervous system, such as epilepsy; psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity, including drug allergy, which was deemed relevant to the study as judged by the investigator
- •Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the study
- •Use of drugs, which might have reasonably influenced the results of the study based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the study
- •Participation in another study with an investigational drug within two months prior to administration or during the study
- •Alcohol abuse (more than 60 g/day)
- •Blood donation; more than 100 mL within four weeks prior to administration or during the study
- •Excessive physical activities; within one week prior to administration or during the study
- •Any laboratory value outside the reference range that was of clinical relevance
- •Inability to comply with dietary regimen of study centre
- •Females of child bearing potential who were pregnant, breast feeding or who were either not surgically sterile or were sexually active and not using an acceptable, i.e. highly effective with a Pearl index >1%, form of contraception as either the oral contraceptives since at least two months and the double barrier method, i.e. intrauterine device with spermicide and condom for the male partner 18.) Male subjects had to agree to minimize the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the post-study medical. Acceptable methods of contraception comprised barrier contraception and a medically accepted contraceptive method for the female partner (intrauterine device with spermicide, hormonal contraceptive since at least two month).
- •19.) Abnormal thyroid stimulating hormone (TSH) at screening
研究组 & 干预措施
Dabigatran etexilate + Amiodarone
Experimental
干预措施: Dabigatran etexilate (Drug)
Dabigatran etexilate + Amiodarone
Experimental
干预措施: Amiodarone (Drug)
Amiodarone
Active Comparator
干预措施: Amiodarone (Drug)
结局指标
主要结局
AUCτ,ss (area under the concentration time curve of the analyte in plasma over one steady state dosing interval)
时间窗: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose on day 3, pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose on day 4
Cmax,ss (maximum concentration of the analyte in plasma at steady state)
时间窗: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose on day 3, pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose on day 4
AUC0-infinity (area under the concentration time curve of the analyte in plasma extrapolated to infinity)
时间窗: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose
Cmax (maximum concentration of the analyte in plasma)
时间窗: pre-dose on day 1 and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose
Changes in aPTT (activated partial thromboplastin time)
时间窗: pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose
Changes in ECT (ecarin clotting time)
时间窗: pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose
AUERτ,ss (area under the effect ratio-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
时间窗: pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose
ERmax,ss (maximum effect ratio in plasma at steady state)
时间窗: pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose
次要结局
- AUC0-tz,ss (area under the concentration-time curve of the analyte in plasma from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)(pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose)
- tz,ss (time of last measurable concentration of the analyte in plasma within the dosing interval τ at steady state)(pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose)
- tmax,ss (time from last dosing to the maximum concentration of the analyte in plasma at steady state on Day 4)(pre-dose Day 4 and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose)
- CL/Fss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)(pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose)
- CLR,ss (renal clearance of the analyte at steady state determined over the dosing interval τ)(pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose)
- Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose)
- tmin,ss (time from last dosing to the minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose)
- Cpre,ss (pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose)(pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose)
- MRTp.o.,ss (mean residence time of the analyte in the body at steady state after oral administration)(pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose)
- Vz/Fss (apparent volume of distribution of the analyte during the terminal phase λz at steady state following an extravascular administration)(pre-dose on Day 1, 2, 3, and 4; on day 3 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 h post-dose; on day 4 pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120 h post-dose)
- Aeτ,ss (amount of the analyte eliminated in urine at steady state over an uniform dosing interval τ)(pre-dose, 0-12 h and 12-24 h post-dose on days 3 and 4)
- feτ,ss (fraction of the analyte eliminated in urine at steady state over a uniform dosing interval τ)(pre-dose, 0-12 h and 12-24 h post-dose on days 3 and 4)
- AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval 0 to the last quantifiable analyte plasma concentration after single dose administration)(pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose)
- t1/2 (terminal half-life of the analyte in plasma after a single dose)(pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose)
- MRTp.o. (mean residence time of the analyte in the body after single dose p.o. administration(pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose)
- CL/F (apparent clearance of the analyte in the plasma after extravascular single dose administration)(pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose)
- Vz/F (apparent volume of distribution of the analyte during the terminal phase λz following extravascular dose)(pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose)
- Changes in physical examination(up to 8 days following drug administration)
- Changes in vital signs (BP, PR)(up to 8 days following drug administration)
- Changes in 12-lead electrocardiogram (ECG)(up to 8 days following drug administration)
- Changes in clinical laboratory tests(up to 8 days following drug administration)
- Occurrence of adverse events(up to 8 days following drug administration)
- Assessment of tolerability by investigator(up to 8 days following drug administration)
- tz (time of last measurable concentration of the analyte in plasma following a single dose)(pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose)
- %AUCtz-infinity (percentage of the AUC0-infinity of the analyte obtained by extrapolation)(pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose)
- tmax (time from dosing to the maximum concentration of the analyte in plasma following a single dose)(pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose)
- λz (terminal rate constant of the analyte in plasma after a single dose)(pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 and 120 h post-dose)
研究者
相似试验
已完成
1 期
Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female VolunteersHealthyNCT02171559Boehringer Ingelheim29
已完成
1 期
Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female VolunteersHealthyNCT02171507Boehringer Ingelheim24
已完成
1 期
Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female VolunteersHealthyNCT02171039Boehringer Ingelheim24
已完成
1 期
Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female VolunteersHealthyNCT02171052Boehringer Ingelheim24
已完成
1 期
Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male SubjectsHealthyNCT02710630Boehringer Ingelheim35